Larimar Therapeutics (LRMR) director receives 55,150 stock options grant

Rhea-AI Filing Summary

Larimar Therapeutics, Inc. director Joseph Truitt reported receiving a stock option grant covering 55,150 shares of common stock. The option has an exercise price of $3.33 per share and expires on May 19, 2036.

These options vest on the earlier of May 19, 2027, or the date of Larimar’s next annual meeting of stockholders, in each case contingent on Truitt’s continued service on the Board of Directors. Following this grant, Truitt holds 55,150 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Truitt Joseph

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 55,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 55,150 options Exercise price: $3.33 per share Expiration date: May 19, 2036 +3 more

6 metrics

Options granted 55,150 options Stock Option (Right to Buy) grant to director

Exercise price $3.33 per share Conversion or exercise price of options

Expiration date May 19, 2036 Option term end date

Vesting date trigger May 19, 2027 or next annual meeting Earlier date governs vesting, subject to board service

Post-transaction options held 55,150 options Total derivative securities following transaction

Transaction code Code A Grant, award, or other acquisition on Form 4

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Board of Directors, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Board of Directors financial

"subject to the Reporting Person's continued service on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

annual meeting of stockholders financial

"the date of the Company's next annual meeting of stockholders"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Truitt Joseph

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PENNSYLVANIA 19004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.33	05/19/2026		A		55,150		(1)	05/19/2036	Common Stock	55,150	$0	55,150	D

Explanation of Responses:

1. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

	/s/ Jennifer Johansson, Attorney-in-fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Larimar Therapeutics (LRMR) disclose for Joseph Truitt?

Larimar Therapeutics disclosed that director Joseph Truitt received a grant of 55,150 stock options. These derivative securities give him the right to buy common stock at a fixed price under the company’s equity compensation arrangements.

How many Larimar Therapeutics (LRMR) options were granted to Joseph Truitt and at what price?

Joseph Truitt was granted 55,150 stock options, each with an exercise price of $3.33 per share. This means he can purchase Larimar common stock at $3.33 once the options vest and before they expire, subject to the grant’s terms.

When do Joseph Truitt’s Larimar Therapeutics (LRMR) stock options vest?

The options vest on the earlier of May 19, 2027 or the date of Larimar’s next annual meeting of stockholders. Vesting in both cases is conditioned on Truitt’s continued service on the company’s Board of Directors through that date.

What is the expiration date of Joseph Truitt’s Larimar Therapeutics (LRMR) stock options?

Joseph Truitt’s stock options expire on May 19, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Larimar Therapeutics common stock at the $3.33 exercise price specified in the grant.

What type of Form 4 transaction code applies to Joseph Truitt’s LRMR option grant?

The transaction is coded “A” on Form 4, indicating a grant, award, or other acquisition of derivative securities. This reflects an options award rather than an open-market stock purchase or sale by Joseph Truitt.

How many Larimar Therapeutics (LRMR) derivative securities does Joseph Truitt hold after this grant?

After this transaction, Joseph Truitt holds 55,150 stock options directly, according to the reported total shares following the transaction. Each option is exercisable for one share of Larimar Therapeutics common stock under the grant terms.